HUP0301305A3 - Use of dopamine d2/d3 receptor agonists for preparation of pharmaceutical compositions to treat fibromyalgia - Google Patents

Use of dopamine d2/d3 receptor agonists for preparation of pharmaceutical compositions to treat fibromyalgia

Info

Publication number
HUP0301305A3
HUP0301305A3 HU0301305A HUP0301305A HUP0301305A3 HU P0301305 A3 HUP0301305 A3 HU P0301305A3 HU 0301305 A HU0301305 A HU 0301305A HU P0301305 A HUP0301305 A HU P0301305A HU P0301305 A3 HUP0301305 A3 HU P0301305A3
Authority
HU
Hungary
Prior art keywords
dopamine
preparation
pharmaceutical compositions
receptor agonists
treat fibromyalgia
Prior art date
Application number
HU0301305A
Other languages
English (en)
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of HUP0301305A2 publication Critical patent/HUP0301305A2/hu
Publication of HUP0301305A3 publication Critical patent/HUP0301305A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
HU0301305A 2000-07-17 2001-07-05 Use of dopamine d2/d3 receptor agonists for preparation of pharmaceutical compositions to treat fibromyalgia HUP0301305A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/617,177 US6277875B1 (en) 2000-07-17 2000-07-17 Use of dopamine D2/D3 receptor agonists to treat fibromyalgia
PCT/US2001/021530 WO2002005797A2 (en) 2000-07-17 2001-07-05 Use of dopamine d2/d3 receptor agonists to treat fibromyalgia

Publications (2)

Publication Number Publication Date
HUP0301305A2 HUP0301305A2 (hu) 2003-08-28
HUP0301305A3 true HUP0301305A3 (en) 2008-03-28

Family

ID=24472575

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301305A HUP0301305A3 (en) 2000-07-17 2001-07-05 Use of dopamine d2/d3 receptor agonists for preparation of pharmaceutical compositions to treat fibromyalgia

Country Status (17)

Country Link
US (2) US6277875B1 (hu)
EP (1) EP1311251A2 (hu)
JP (1) JP2004503587A (hu)
KR (1) KR100797603B1 (hu)
CN (1) CN1443066A (hu)
AU (2) AU2001271910B2 (hu)
BR (1) BR0112476A (hu)
CA (1) CA2414774C (hu)
CZ (1) CZ2003417A3 (hu)
HU (1) HUP0301305A3 (hu)
IL (1) IL153915A0 (hu)
MX (1) MXPA03000336A (hu)
NO (1) NO20030213L (hu)
NZ (1) NZ523926A (hu)
PL (1) PL360121A1 (hu)
WO (1) WO2002005797A2 (hu)
ZA (1) ZA200300588B (hu)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5522301A (en) * 2000-04-21 2001-11-26 Upjohn Co Treatment of fibromyalgia and chronic fatigue syndrome
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
WO2002069974A1 (en) * 2001-03-05 2002-09-12 Andrew Holman Administration of sleep restorative agents
DE10137162A1 (de) * 2001-07-30 2003-02-20 Hexal Ag Matrixkontrolliertes transdermales therapeutisches System zur Anwendung von Pramiprexol und Ropinirol
DE10138275A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Verbindungen zur Beseitigung der Anhedonie
GB0125088D0 (en) * 2001-10-18 2001-12-12 Smithkline Beecham Cork Ltd New use
US7079888B2 (en) * 2002-04-11 2006-07-18 Ansar, Inc. Method and apparatus for monitoring the autonomic nervous system using non-stationary spectral analysis of heart rate and respiratory activity
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
US20070196481A1 (en) * 2002-07-25 2007-08-23 Amidon Gregory E Sustained-release tablet composition
US8679533B2 (en) * 2002-07-25 2014-03-25 Pharmacia Corporation Pramipexole once-daily dosage form
US20050226926A1 (en) * 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
US20040092504A1 (en) * 2002-11-12 2004-05-13 Anuthep Benja-Athon Definitive medications for treating fibromyalgia
DE60204229T2 (de) * 2002-12-02 2006-02-02 Schwarz Pharma Ag Verabreichung von Rotigotine zur Behandlung der Parkinson'schen Krankheit durch Iontophorese
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
KR101052436B1 (ko) * 2004-08-13 2011-07-29 베링거 인겔하임 인터내셔날 게엠베하 프라미펙솔 또는 약제학적으로 허용되는 이의 염을함유하는 연장 방출형 정제 제형, 이의 제조방법 및 이의용도
KR20070050081A (ko) * 2004-08-13 2007-05-14 베링거 인겔하임 인터내셔날 게엠베하 프라미펙솔 또는 약제학적으로 허용되는 이의 염을포함하는 연장 방출형 펠렛 제형, 이의 제조방법 및 이의용도
WO2007048034A2 (en) * 2005-10-21 2007-04-26 Caritas St. Elizabeth Medical Center Of Boston, Inc. Use of androgens for the treatment of parkinson' s disease
WO2007090883A1 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
WO2007090881A2 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Modified release formulation
TWI392670B (zh) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
CN1944647B (zh) * 2006-08-23 2010-05-12 华东师范大学 多巴胺受体新亚型d5b基因及编码的蛋白与应用
GB0700786D0 (en) * 2007-01-15 2007-02-21 Pfizer Ltd Morpholine dopamine agonists for the treatment of pain
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
WO2010023693A2 (en) * 2008-09-01 2010-03-04 Lupin Limited Novel controlled release compositions of ropinirole
CA2738414C (en) 2008-09-29 2014-05-27 Wockhardt Research Centre Extended release dosage form of ropinirole
WO2010044108A2 (en) 2008-10-17 2010-04-22 Rubicon Research Private Limited Controlled release formulations of ropinirole
UA103851C2 (en) 2010-04-30 2013-11-25 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Propylaminoindan transdermal composition
WO2012129429A2 (en) 2011-03-24 2012-09-27 Teikoku Pharma Usa, Inc. Transdermal compositions comprising an active agent layer and an active agent conversion layer
JP5913614B2 (ja) 2011-11-09 2016-04-27 テイコク ファーマ ユーエスエー インコーポレーテッド 皮膚新生物の処置方法
WO2014070622A1 (en) 2012-11-02 2014-05-08 Teikoku Pharma Usa, Inc. Propynylaminoindan transdermal compositions
MA41125A (fr) * 2014-12-05 2017-10-10 Purdue Pharma Lp Dérivés de 6.7-cyclomorphinane et leur utilisation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4414224A (en) * 1980-08-22 1983-11-08 Smithkline Beckman Corporation Pharmaceutical composition and methods for producing dopamine agonist activity
US4879391A (en) * 1982-09-20 1989-11-07 Pfizer Inc. 1-Phenyl-2(1H,3H)-indolone psychotherapeutic agents
US4452808A (en) * 1982-12-07 1984-06-05 Smithkline Beckman Corporation 4-Aminoalkyl-2(3H)-indolones
DE3447075A1 (de) * 1984-12-22 1986-07-03 Dr. Karl Thomae Gmbh, 7950 Biberach Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arzneimittel
ATE45735T1 (de) * 1984-12-22 1989-09-15 Thomae Gmbh Dr K Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arnzneimittel.
GB8712073D0 (en) * 1987-05-21 1987-06-24 Smith Kline French Lab Medicament
US5498610A (en) * 1992-11-06 1996-03-12 Pfizer Inc. Neuroprotective indolone and related derivatives
US5696128A (en) 1994-07-07 1997-12-09 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method of regulating immune function
US5658955A (en) 1994-11-01 1997-08-19 Hitzig; Pietr Combined use of dopamine and serotonin agonists in the treatment of immune disorders
AU5522301A (en) * 2000-04-21 2001-11-26 Upjohn Co Treatment of fibromyalgia and chronic fatigue syndrome

Also Published As

Publication number Publication date
IL153915A0 (en) 2003-07-31
MXPA03000336A (es) 2005-04-19
US6300365B1 (en) 2001-10-09
CZ2003417A3 (cs) 2003-08-13
EP1311251A2 (en) 2003-05-21
HUP0301305A2 (hu) 2003-08-28
CA2414774C (en) 2010-09-07
ZA200300588B (en) 2004-04-22
CA2414774A1 (en) 2002-01-24
NZ523926A (en) 2006-05-26
US6277875B1 (en) 2001-08-21
CN1443066A (zh) 2003-09-17
KR100797603B1 (ko) 2008-01-28
WO2002005797A8 (en) 2003-03-06
AU7191001A (en) 2002-01-30
JP2004503587A (ja) 2004-02-05
NO20030213D0 (no) 2003-01-16
WO2002005797A2 (en) 2002-01-24
BR0112476A (pt) 2003-07-22
PL360121A1 (en) 2004-09-06
KR20030029625A (ko) 2003-04-14
NO20030213L (no) 2003-03-11
AU2001271910B2 (en) 2005-07-28

Similar Documents

Publication Publication Date Title
HUP0301305A3 (en) Use of dopamine d2/d3 receptor agonists for preparation of pharmaceutical compositions to treat fibromyalgia
HUP0103767A3 (en) Use of estrogen agonist/antagonist for preparation of pharmaceutical compositions available for treating osteoarthritis
HUP0100120A2 (en) Pharmaceutical compositions comprising estrogen agonists/antagonists suitable for treating conditions responsive to estrogen
HUP0301346A3 (en) New combination of serotonin agonist (5ht2) and antagonist (5ht6) as pharmaceutical composition and process for its preparation
IL165279A (en) Use of alpha-adrenergic agonists and alpha-2a antagonists for the preparation of pharmaceutical compositions for alleviating pain
HUP0204229A3 (en) Compositions oral opioid formulations, compositions process for their preparation and their use
HUP0303432A3 (en) Substituted pyridoindoles as serotonin agonists and antagonists and pharmaceutical compositions containing the compounds and their use
HUP0102160A3 (en) Use of alpha-keto enamine derivatives as ingredients
HUP0103558A3 (en) Pharmaceutical composition containing nmda receptor antagonist for the treatment of stroke and traumatic brain insury
IL198996A (en) Use of a tyrosine kinase inhibitor for its preparation as a medicinal preparation
HUP0300565A3 (en) 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
HUP0004120A3 (en) Use of cgmp-pde5 inhibitors for the preparation of pharmaceutical compositions treating neuropathy
IS6811A (is) Lyfjafræðilegar samsetningar NMDA viðtakagerandefna
HUP0104406A3 (en) Use of pde v inhibitors for the preparation of pharmaceutical compositions increasing fecundity in mammals
HUP0202399A3 (en) Use of dopamine d3 receptor ligands for producing pharmaceutical compositions for treating kidney disorders
IL151369A (en) Use of tgf-beta antagonist for the preparation of pharmaceuticals
HUP0301075A3 (en) Diphenyl ether derivatives, their use for preparation of pharmaceutical compositions and process for preparation the compounds
HUP0303731A3 (en) Sulfonylguanidines and their use for preparation of pharmaceutical compositions
HUP0301317A3 (en) Use of neuroprotective 7-beta-hydroxysteroids for preparation of pharmaceutical compositions
HUP0402358A3 (en) Use of selective dopamine d4 receptor agonists for preparation of pharmaceutical composition for treating sexual dysfunction
HUP0102159A3 (en) Pharmaceutical composition for the treatment of rumen acidosis
HUP0300694A3 (en) Indole derivatives as mcp-1 receptor antagonists, their use, process for their preparation and pharmaceutical compositions containing them
HUP0204324A3 (en) Use of fsh for preparation of pharmaceutical composition suitable for treating infertility
HUP0301784A3 (en) Biphenyl derivatives, of imidazole and benzimidazole the use thereof, process for the preparation of compounds and pharmaceutical compositions containing them
HUP0200311A3 (en) Use of aroyl- or arylalkanoylpyridazines for preparation of pharmaceutical compositions

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: INMEDIX, LLC, US

Free format text: FORMER OWNER(S): HOLMAN, ANDREW J., US

GB9A Succession in title

Owner name: BOEHRINGER INGELHEIM INTERNATIONAL GMBH, DE

Free format text: FORMER OWNER(S): INMEDIX, LLC, US; HOLMAN, ANDREW J., US

FD9A Lapse of provisional protection due to non-payment of fees